NCT00911261View on ClinicalTrials.gov

Oxymorphone Extended Release in Patients With Cancer or Neuropathic Pain

PHASE3CompletedINTERVENTIONAL
Enrollment

223

Participants

Timeline

Start Date

August 31, 2003

Primary Completion Date

March 31, 2005

Study Completion Date

May 31, 2005

Conditions
Chronic PainNeuropathic PainCancer
Interventions
DRUG

Oxymorphone Extended Release

"* Study Medication: Oxymorphone ER 5 mg, 10 mg, 20 mg, and 40 mg tablets~* Rescue Medication: Oxymorphone IR 5 mg and 10 mg tablets~* Treatment will consist of up to 12 months of dosing with Oxymorphone ER."

Sponsors
All Listed Sponsors
lead

Endo Pharmaceuticals

INDUSTRY